Study: NCT01215916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636
Description: Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636
Description: Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636
Description: Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid \[350 micrograms (µg) to 1000 µg orally, daily\], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone \[4 milligrams (mg) orally, twice daily or equivalent\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 375 to 500 milligrams per square meter (mg/m\^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent).